Kiora Pharmaceuticals, Inc.
KPRX
$2.84
$0.1917.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.13% | 50.33% | -33.21% | 21.40% | -93.24% |
| Gross Profit | -29.69% | -117.69% | 33.21% | -21.40% | 94.68% |
| SG&A Expenses | -11.97% | 14.89% | 50.68% | -2.46% | 40.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.62% | -26.34% | 25.80% | 7.89% | -1.80% |
| Operating Income | 6.86% | -115.56% | -25.80% | -7.89% | 2.60% |
| Income Before Tax | -1.93% | -115.39% | 0.91% | 40.77% | 15.00% |
| Income Tax Expenses | -- | -- | 2,186.82% | -- | -- |
| Earnings from Continuing Operations | 3.11% | -116.30% | -86.17% | 40.77% | 15.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.11% | -116.30% | -86.17% | 40.77% | 15.00% |
| EBIT | 6.86% | -115.56% | -25.80% | -7.89% | 2.60% |
| EBITDA | 6.75% | -115.55% | -26.00% | -8.30% | 1.97% |
| EPS Basic | -1.30% | -111.14% | 63.10% | 89.84% | 92.55% |
| Normalized Basic EPS | -5.81% | -109.12% | 80.49% | 79.95% | 92.54% |
| EPS Diluted | -1.37% | -115.03% | 63.12% | 89.84% | 92.55% |
| Normalized Diluted EPS | -5.81% | -112.32% | 80.49% | 79.95% | 92.54% |
| Average Basic Shares Outstanding | -4.35% | 46.33% | 404.57% | 433.75% | 1,041.07% |
| Average Diluted Shares Outstanding | -4.35% | 8.36% | 404.57% | 433.75% | 1,041.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |